当前位置: 首页 >> 检索结果
1081. Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial.
作者: Weili Li.;Jing Lan.;Ming Wei.;Lan Liu.;Chengbei Hou.;Zhifeng Qi.;Chuanhui Li.;Liqun Jiao.;Qi Yang.;Wenhuo Chen.;Shuling Liu.;Xincan Yue.;Qinglin Dong.;Haicheng Yuan.;Zongen Gao.;Xiangbin Wu.;Changming Wen.;Tong Li.;Changchun Jiang.;Di Li.;Zuoquan Chen.;Junfeng Shi.;Wanchao Shi.;Jinglin Yuan.;Yijie Qin.;Binglong Li.;Marc Fisher.;Wuwei Feng.;Ke Jian Liu.;Xunming Ji.; .
来源: Lancet. 2025年405卷10477期486-497页
Endovascular treatment improves the recanalisation rate for patients with acute ischaemic stroke; however, even with endovascular treatment, approximately half of patients do not have a favourable functional outcome. We aimed to evaluate the effect of normobaric hyperoxia combined with endovascular treatment on functional outcomes up to 90 days after treatment in patients who had an acute ischaemic stroke with large-vessel occlusion.
1100. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
作者: Nirosen Vijiaratnam.;Christine Girges.;Grace Auld.;Rachel McComish.;Alexa King.;Simon S Skene.;Steve Hibbert.;Alan Wong.;Sabina Melander.;Rachel Gibson.;Helen Matthews.;John Dickson.;Camille Carroll.;Abigail Patrick.;Jemma Inches.;Monty Silverdale.;Bethan Blackledge.;Jessica Whiston.;Michele Hu.;Jessica Welch.;Gordon Duncan.;Katie Power.;Sarah Gallen.;Jacqueline Kerr.;K Ray Chaudhuri.;Lucia Batzu.;Silvia Rota.;Edwin Jabbari.;Huw Morris.;Patricia Limousin.;Nigel Greig.;Yazhou Li.;Vincenzo Libri.;Sonia Gandhi.;Dilan Athauda.;Kashfia Chowdhury.;Tom Foltynie.
来源: Lancet. 2025年405卷10479期627-636页
GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.
|